四重療法 – Medxy AI

Economic Impact and Clinical Benefits of Quadruple Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review

By MedXY 07/03/2026

This review synthesizes evidence demonstrating that implementing full quadruple GDMT (ARNI, β-blockers, MRAs, SGLT2i) in HFrEF reduces hospitalization risks and healthcare costs, often yielding net savings despite medication expenses.

Cardiology news

Only 1 in 5 Veterans with Heart Failure Achieve Recommended Quadruple Therapy Within 3 Years—What This Means for Clinical Practice

By MedXY 04/05/2026

A large retrospective study of 52,850 veterans reveals that just 21.2% achieve guideline-directed quadruple therapy for HFrEF, with a median time of 197 days. Socioeconomic barriers, including prescription copays, emerge as critical modifiable factors hindering optimal treatment uptake.

Cardiology Clinical Updates news

Residual Clinical Risk and Economic Burden in HFrEF: Insights from the Quadruple Medical Therapy Era

By MedXY 03/14/2026

This review analyzes the real-world one-year outcomes and healthcare costs for HFrEF patients on quadruple therapy, revealing significant residual risk despite optimized pharmacologic management.